Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

2019

Bone Therapeutics holds successful event to highlight strength of cell and gene therapy in Wallonia

  • Read more about Bone Therapeutics holds successful event to highlight strength of cell and gene therapy in Wallonia

Bone Therapeutics: Information on the total number of voting rights and shares (January 2019)

  • Read more about Bone Therapeutics: Information on the total number of voting rights and shares (January 2019)

Bone Therapeutics to present at the Annual Meeting of the Orthopaedic Research Society (ORS)

  • Read more about Bone Therapeutics to present at the Annual Meeting of the Orthopaedic Research Society (ORS)

Bone Therapeutics Notice of Full Year 2018 Results

  • Read more about Bone Therapeutics Notice of Full Year 2018 Results

Bone Therapeutics announces 2018 full year results

  • Read more about Bone Therapeutics announces 2018 full year results

Bone Therapeutics: Information on the total number of voting rights and shares (February 2019)

  • Read more about Bone Therapeutics: Information on the total number of voting rights and shares (February 2019)

Bone Therapeutics appoints Olivier Godeaux as Chief Medical Officer and Benoit Moreaux as Chief Scientific and Technology Officer

  • Read more about Bone Therapeutics appoints Olivier Godeaux as Chief Medical Officer and Benoit Moreaux as Chief Scientific and Technology Officer

Bone Therapeutics to present at Herbert Fleisch / IFMRS Workshop

  • Read more about Bone Therapeutics to present at Herbert Fleisch / IFMRS Workshop

Bone Therapeutics: Information on the total number of voting rights and shares (March 2019)

  • Read more about Bone Therapeutics: Information on the total number of voting rights and shares (March 2019)

The preliminary documents for the Extraordinary General Shareholder Meeting on 23 May 2019 have been made available

  • Read more about The preliminary documents for the Extraordinary General Shareholder Meeting on 23 May 2019 have been made available

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to 2019
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions